We observed significant reduction in the viability of KRAS-Mutant pancreatic cancer lines and almost no effect on KRAS-WT lines (Figure S5), further establishing the selective growth inhibitory effect of miR-126 on KRAS-Mutant cells. Here, KRAS is linked to pancreatic neoplasm.